Understanding myeloid disorders with next-generation sequencing

Tuesday 24 January 2017
Product types:

In this whitepaper, the team from the Haemato-Oncology section of the West Midlands Regional Genetics Laboratory (WMRGL) of Birmingham Women’s NHS Foundation Trust in the UK discuss the introduction of a SureSeq NGS cancer panel, highlighting the ease of adoption and two occasions where mutations missed by digital droplet PCR (ddPCR) were picked up by the NGS panel.

Before you can download this please fill in some details.

Must be a valid email address

By responding to this form, you are indicating that you have read the Privacy Policy and agree to the Website Terms of Use.